{"created":"2023-05-15T14:56:03.627564+00:00","id":76134,"links":{},"metadata":{"_buckets":{"deposit":"f473a46a-2814-466e-927f-de0d42a6c1ca"},"_deposit":{"created_by":1,"id":"76134","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"76134"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00076134","sets":["10:29"]},"author_link":["765073","765065","765066","765079","765071","765068","765074","765067","765072","765070","765069","765078","765077","765075","765080","765076"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2019-06-24","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: Pancreatic cancer has a very poor prognosis. Surgery is the primary treatment for patients with resectable pancreatic cancer; however, local recurrence, hepatic metastasis, and peritoneal dissemination often occur even after extensive surgery. Adjuvant chemotherapy, typically with gemcitabine, has been used clinically, but with a modest survival benefit. To achieve a better outcome, we investigated the efficacy of 64Cu-intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab as an adjuvant treatment after pancreatic cancer surgery using an orthotopic xenografted mouse model. Methods: Efficacy of adjuvant 64Cu-ipRIT was investigated in a human pancreatic cancer mouse model harboring orthotopic xenografts of XPA-1DC cells. To reproduce clinical situation, pancreatic cancer xenograft was surgically resected at the point when primary tumors were visible in the pancreas, but obvious metastatic lesions were not yet apparent. Tumor development were observed with the aid of a stereoscopic fluorescence microscope. The dose-effect relationship in toxicity for intraperitoneally injected 64Cu- cetuximab was examined to determine therapeutic dose. For adjuvant 64Cu-ipRIT, 22.2 MBq 64Cu-cetuximab was injected intraperitoneally into mice one day after surgery and the survival was compared to the surgery-only control. For comparison, adjuvant chemotherapy with gemcitabine was also examined using the same model. Results: We established a mouse model that developed not only primary tumors in the pancreas but also subsequently reproduced local recurrence, hepatic metastasis, and peritoneal dissemination after surgery like pancreatic cancer patients. Adjuvant 64Cu-ipRIT with 64Cu-labeled cetuximab after surgery showed significant improvement of survival compared to surgery only control and effectively suppressed local recurrence, hepatic metastasis, and peritoneal dissemination with little toxicity in this model. Adjuvant chemotherapy with gemcitabine nominally prolonged the survival but the effect was not statistically significant. Conclusion: 64Cu-ipRIT with cetuximab can be an effective adjuvant therapy after pancreatic cancer surgery.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":" The  Society of Nuclear Medicine and Molecular Imaging(SNMMI) annual meeting 2019","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshii, Yukie"}],"nameIdentifiers":[{"nameIdentifier":"765065","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsumoto, Hiroki"}],"nameIdentifiers":[{"nameIdentifier":"765066","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimoto, Mitsuyoshi"}],"nameIdentifiers":[{"nameIdentifier":"765067","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang"}],"nameIdentifiers":[{"nameIdentifier":"765068","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagatsu, Kotaro"}],"nameIdentifiers":[{"nameIdentifier":"765069","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya"}],"nameIdentifiers":[{"nameIdentifier":"765070","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"765071","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"765072","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshii, Yukie","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765073","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsumoto, Hiroki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765074","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimoto, Mitsuyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765075","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765076","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagatsu, Kotaro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765077","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765078","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765079","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"765080","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-06-27"},"publish_date":"2019-06-27","publish_status":"0","recid":"76134","relation_version_is_last":true,"title":["Adjuvant intraperitoneal radioimmunotherapy (ipRIT) with 64Cu-cetuximab extends postsurgical survival by attenuating recurrences in a clinically-relevant orthotopic pancreatic cancer xenograft mode"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T00:37:00.454208+00:00"}